Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.46 |
| ▸ | FABP3 | P05413 | 5/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032620 | 1.00 | LPAR3 (0.50) | LPAR3LPAR2TSHRGGPS1LPAR1 | |
| SCHEMBL699777 | 1.00 | LPAR3 (0.50) | LPAR3LPAR2TSHRGGPS1LPAR1 | |
| SCHEMBL482879 | 0.98 | LPAR3 (0.48) | LPAR3LPAR2TSHRGGPS1LPAR1 | |
| SCHEMBL6626608 | 0.90 | — | — | |
| SCHEMBL103934 | 0.79 | — | — | |
| SCHEMBL27865664 | 0.78 | LPAR2 (0.33) | LPAR3LPAR2TSHRLPAR1 | |
| Phosphoric Acid SCHEMBL11225058 | 0.78 | LPAR3 (0.64) | LPAR3LPAR2GGPS1LPAR1FABP3 | |
| Phosphoric Acid SCHEMBL3911255 | 0.78 | LPAR3 (0.64) | LPAR3LPAR2GGPS1LPAR1FABP3 | |
| SCHEMBL2978872 | 0.77 | LPAR3 (0.53) | LPAR3LPAR2GGPS1LPAR1FABP3 | |
| SCHEMBL11221963 | 0.77 | LPAR3 (0.53) | LPAR3LPAR2GGPS1LPAR1FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252584-B1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-8445292-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120107942-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8163910-B2 | Amide-substituted xanthene dyes | ELITECH HOLDING B.V. (NL) | 2012-04-24 | — | — | US | disclosed |
| US-8124792-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2252584-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | Prozyme, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009100155-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090093612-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009046165-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | EPOCH BIOSCIENCES, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1227098-B1 | TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS | OTSUKA PHARMA CO LTD (JP) | 2004-04-28 | — | — | EP | disclosed |
| US-6686343-B1 | Triazolopurine derivatives, pharmaceutical compositions containing the derivatives, and adenosine A3 receptor affinitive agents | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-02-03 | — | — | US | disclosed |
| EP-1227098-A1 | TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | B3GNT2, FUT5, FUT6 | LPAR3 1908/4885LPAR2 3009/4885TSHR 612/4885 |
| US-20090093612-A1 | AMIDE-SUBSTITUTED XANTHENE DYES | ANXA5, PHOSPHO1, TPST2 | LPAR3 446/4885LPAR2 952/4885TSHR 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.